Jessica Karen Wong, MD, MEng

Dr. Jessica Wong
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Assistant Professor, Department of Radiation Oncology
Assistant Director, Radiation Oncology Residency and Fellowship Training Program

Specialties

Treatment Focus

Stereotactic Body Radiation Therapy (SBRT), Intensity Modulated Radiation Therapy (IMRT), Hypofractionated Radiation Therapy, High Dose Rate Prostate Brachytherapy, Anal Cancer

Key Awards

RSNA Roentgen Resident/Fellow Research Award 2019

Treatment Philosophy

I chose to join the Radiation Oncology faculty at Fox Chase after completing my training here because I believe that cancer is best treated in a multidisciplinary setting with the highest standard of clinical care. Here, cancer patients receive outstanding, compassionate treatment delivered with state of the art technology. I strive to maintain strong relationships with my patients and work with them to develop personalized treatment plans for their individual needs. I particularly enjoy our multi-disciplinary approach, as I feel that much more can be accomplished when people of different backgrounds and expertise work together on a common goal.

My primary treatment site is genitourinary malignancies, where I treat patients with both external beam radiation and brachytherapy. I am particularly interested in Prostate High Dose Rate (HDR) Brachytherapy which can reduce toxicity for certain patients while maintaining excellent cancer control. Prostate cancer has also been the focus of my academic interests and I have multiple active clinical and translational studies, including a national study comparing moderately-hypofractionated intensity modulated radiation therapy (IMRT) and proton radiation therapy.

After earning my Bachelor of Science in Chemical-Biological Engineering at the Massachusetts Institute of Technology and a Master’s of Engineering in Biomedical Engineering through the Harvard-MIT Division of Health Science and Technology, I attended medical school at the University of Tennessee. I believe the combination of my science and engineering background with my clinical training gives me a unique perspective to pursue clinical and translational research. Having a strong science background allows me to determine what scientific investigations are feasible and having a strong clinical background allows me to ensure that experiments are clinically relevant, allowing for the most immediate impact on patient care. I seek to further the understanding of radiation’s interaction with the body to improve treatment techniques and develop novel cancer treatments.

In addition to quality patient care and cutting-edge research, I also enjoy radiation oncology education and mentorship. I am active in the American Society for Radiation Oncology (ASTRO), Society of Women in Radiation Oncology (SWRO), American Brachytherapy Society (ABS), Association for Directors of Radiation Oncology Programs (ADROP), and Radiation Oncology Education Collaborative Study Group (ROECSG). I am proud to serve as the Assistant Director of our radiation oncology residency program and fellowship training program as our talented medical students, residents, and fellows are the future of our field.

Educational Background

  • Chief Resident, Fox Chase Cancer Center, Philadelphia, PA, 2018-2019
  • Resident, Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, 2016–2020
  • Resident, Preliminary Medicine, University of Tennessee, Memphis, TN, 2016
  • MD, University of Tennessee College of Medicine, Memphis, TN, 2015
  • MEng Biomedical Engineering, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, 2011
  • BS, Chemical-Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 2010

Memberships

  • American Society for Radiation Oncology (ASTRO)
  • American Brachytherapy Society (ABS)
  • Association for Directors of Radiation Oncology Programs (ADROP)
  • Radiation Oncology Education Collaborative Study Group (ROECSG)
  • Society of Women in Radiation Oncology (SWRO)

Honors & Awards

  • RSNA Roentgen Resident/Fellow Research Award 2019

Bob Sokolove

  • Prostate Cancer

I’m 68 years old and a very active person. When I’m not busy working as a lawyer for a firm in Bucks County, which is just north of Philadelphia, you can find me riding my bike, playing and watching sports, or traveling with my wife, Caroline. I’ve never been the wait-and-see type.

VIEW PATIENT STORY

Research Interests

Prostate Cancer, High Dose Rate Brachytherapy, Translational Research, Radio-Immunotherapy

Selected Publications

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050. PubMed PMID: 37856213.

Lee CT, Koleoso O, Deng M, Veltchev I, Lin T, Hallman MA, Horwitz EM, Wong JK. A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. 2023 Sep-Oct;22(5):586-592. doi: 10.1016/j.brachy.2023.06.003. Epub 2023 Jun 30. PubMed PMID: 37393186; PubMed Central PMCID: PMC10527788.


Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men with Very-High Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023. PMID 36179990


Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063. PubMed PMID: 36509074.


Lee CT, Ruth K, Patel S, Bleicher R, Sigurdson E, Weiss S, Hayes S, Anderson P, Wong JK. Factors Associated with Reconstruction Failure and Major Complications After Postmastectomy Radiation to a Reconstructed Breast. Prac Radiat Oncol. 2022. PMID: 36332800


Zhang E, Ruth KJ, Buyyounouski MK, Price RA Jr, Uzzo RG, Sobczak ML, Pollack A, Wong JK, Chen DYT, Hallman MA, Greenberg RE, Watkins-Bruner D, Al-Saleem T, Horwitz EM. Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity Modulated Radiation Therapy for Men with Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID 36566906


Magee DE, Wong JK, Correa AF. Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment. Eur Urol. 2022. PMID: 35945083

Kishan AU, Karnes J, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby W, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martinez Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AM, Pisansky TM, Choo R, Song DY, Greco S, Curtiland D, McNutt T, DeWeese TL, Ross AE, Chong JN, Ciezki JP, Boutros PC, Nickols NG, Bhatt P, Shabsovich D, Juarez J, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients with High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open 2021;4(7):e2115312. PMID: 34196715 doi:10.1001/jamanetworkopen.2021.15312

Xiang M, Ma TM, Savjani R, Pollom E, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedd TB, Lilleby WA, Riano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese T, Ross AD, Ciezki JP, Boutros PC, Nockols NG, Bhat P, Shabsovich D, Juarez JE, Chong B, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Stenberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU Performance of a Prostate-Specific Membrane Antigen Postitron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open 2021;4(12):e2138550. PMID: 34902034 doi:10.1001/jamanetworkopen.2021.38550

Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology. 2021 DOI: 10.1016/j.eururo.2021.04.035. PMID: 33985797

Paly JJ, Egleston B, Wong JK, Burbure N, Sobczak ML, Hayes SB, Chen DY, Horwitz EM, Hallman MA. Patient reported quality of life after short course radiation for prostate cancer: A comparison of LDR, HDR, and SBRT outcomes. Am J Clin Oncol. 2021 DOI: 10.1097/COC.000000000000079

Wong JK, Handorf E, Lee DY, Jain R, Zhang E, Cooper HS, Farma JM, Dotan E, Meyer JE, Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. J. Geriatr Oncol. 2020 DOI:10.1016/j.jgo.2020.04.005, PMID: 32381438

Wong JK, Shaikh T, DeMora L, Zhang E, Borghaei H, Hayes SB, Kumar S, Meyer JE, Hallman MA. Predictors of distant recurrence following stereotactic body radiation therapy for stage I non-small cell lung cancer. Am J Clin Oncol. 2020 DOI: 10.1097/COC.0000000000000662, PMID: 31913907

Levin-Epstein R, Cook R, Wong JK, Stock RG, Demanes DJ, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw HP, Buyyounouski MK, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer E, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients. Radiotherapy and Oncology. 2020 DOI:https://doi.org/10.1016/j.radonc.2020.07.014

Avkshtol V, Ruth KJ, Hallman MA, Greenberg RE, Price RA, Leachman B, Uzzo RG, Ma C, Chen D, Geynisman DM, Zhang E, Wong JK, Pollack A, Horwitz EM. 10-year Update of a Randomized Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer. J Clin Oncol. 2020 DOI:  10.1200/JCO.19.01485 PMID: 32119599

Pai Panandiker AS, Wong JK, Nedelka MA, Wu S, Gajjar A, Broniscer A. (2014), Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2014 PMID: 24482196
 

Additional Publications

MyNCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​
Resize Text

Related Articles